Context Hypoglycemia in people with diabetes is common, especially in those taking
medications such as insulin and sulfonylureas (SU) that place them at higher risk …

Objective To examine the safety, effectiveness, and cost effectiveness of long acting insulin
for type 1 diabetes. Design Systematic review and network meta-analysis. Data sources …

Background: Insulin analogues may be associated with fewer episodes of hypoglycemia
than conventional insulins. However, they are costly alternatives. We compared the cost …

Background Chronic kidney disease (CKD) is a progressive condition that leads to
irreversible damage to the kidneys and is associated with an increased incidence of …

Mainstream health economic theory implies that an expected gain in health-related quality of
life (HRQoL) produces the same value for consumers, regardless of baseline health. Several …

Aims This study assessed the cost‐effectiveness of long‐acting insulin analogues (LAIAs) vs
intermediate/long‐acting human insulin (ILAHI) for patients with type 1 diabetes (T1D) in real …

Abstract Aims This analysis evaluated HbA 1c-adjusted hypoglycemia risk with glargine
versus neutral protamine Hagedorn (NPH) over a 5-year study in patients with Type 2 …

Diabetes mellitus is a major healthcare concern from both a treatment and a funding
perspective. Although decision makers frequently rely on models to evaluate the long-term …

Objectives To compare real-world outcomes of initiating insulin glargine (GLA) versus
neutral protamine Hagedorn (NPH) insulin among employees with type 2 diabetes mellitus …

Background Critiques of cost-effectiveness modelling in type 1 diabetes mellitus (T1DM) are
scarce and are often undertaken in combination with type 2 diabetes mellitus (T2DM) …